Verrica Pharmaceuticals Inc
NASDAQ:VRCA

Watchlist Manager
Verrica Pharmaceuticals Inc Logo
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
Watchlist
Price: 0.6738 USD 8.15% Market Closed
Market Cap: 62.3m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

VRCA Price Targets Summary
Verrica Pharmaceuticals Inc

Wall Street analysts forecast VRCA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VRCA is 3.4 USD with a low forecast of 2.02 USD and a high forecast of 5.25 USD.

VRCA Lowest Forecast
Wall Street Target
2.02 USD
200% Upside
VRCA Average Forecast
Wall Street Target
3.4 USD
405% Upside
VRCA Highest Forecast
Wall Street Target
5.25 USD
679% Upside
Lowest
Price Target
2.02 USD
200% Upside
Average
Price Target
3.4 USD
405% Upside
Highest
Price Target
5.25 USD
679% Upside
Verrica Pharmaceuticals Inc Competitors:
Price Targets
AARTIDRUGS
Aarti Drugs Ltd
1% Downside
688185
CanSino Biologics Inc
15% Upside
VIRP
Virbac SA
22% Upside
SUPN
Supernus Pharmaceuticals Inc
24% Upside
AARTIDRUGS
Aarti Drugs Ltd
1% Downside
688185
CanSino Biologics Inc
15% Upside
VIRP
Virbac SA
22% Upside
SUPN
Supernus Pharmaceuticals Inc
24% Upside
H
200670
Humedix Co Ltd
11% Upside
600332
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
0% Upside
688166
BrightGene Bio-Medical Technology Co Ltd
20% Downside
B
3613
Beijing Tong Ren Tang Chinese Medicine Co Ltd
31% Upside

Revenue
Forecast

Revenue Estimate
Verrica Pharmaceuticals Inc

The compound annual growth rate of Verrica Pharmaceuticals Inc's revenue for the next 3 years is 96%.

N/A
Past Growth
96%
Estimated Growth
Estimates Accuracy
9%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Verrica Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Verrica Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-73%
Average Miss
What are analyst estimates?

See Also

Summary
VRCA intrinsic value, competitors valuation, and company profile.
DCF Valuation
VRCA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VRCA stock valuation using valuation multiples.
Wall Street Estimates
VRCA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VRCA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VRCA's stock price target?
Price Target
3.4 USD

According to Wall Street analysts, the average 1-year price target for VRCA is 3.4 USD with a low forecast of 2.02 USD and a high forecast of 5.25 USD.

What is Verrica Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
96%

The compound annual growth rate of Verrica Pharmaceuticals Inc's revenue for the next 3 years is 96%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 261,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.